跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03883607
NCT03883607终止2 期

An Open Label, Randomized, Multicenter Study to Assess the Pharmacokinetic and Pharmacodynamic Profile and the Safety and Tolerability of Two Dose Levels of Elafibranor (80 mg and 120 mg) in Children and Adolescents, 8 to 17 Years of Age, With Nonalcoholic Steatohepatitis (NASH)

Genfit2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2019年6月25日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
发起方
Genfit
入组人数
10
试验地点
2
主要终点
Pharmacokinetics: Terminal Elimination Half-life ( t½) of Elafibranor and Active Metabolite (GFT1007)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children and adolescent population (8 to 17 years of age) with non alcoholic steatohepatitis (NASH).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
8 Years 至 17 Years（Child）
性别
All
接受健康志愿者
否

入选标准

  • •Was male or female between 8 and 17 years of age (inclusive) at the time of Screening Visit (when consent for study participation is given) and at the time of Randomization;
  • •Diagnosis of NASH confirmed by histological evaluation (with or without fibrosis) from a liver biopsy obtained within 24 months prior to Randomization;
  • •Had an alanine aminotransferase (ALT) level greater than (>) 50 international units per liter (IU/L), at Screening;
  • •Had a Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) greater than or equal to (>=) 5, at Screening;
  • •Had a Body Mass Index z-score (BMI z-score) (also referred to as BMI-for-age percentile) >=85th percentile for age and gender at Screening;
  • •Had a Hemoglobin A1C (HbA1c) less than or equal (<=) to 8.5%. If the participants had Type 2 diabetes and is taking anti-diabetic therapy (e.g., metformin or insulin), treatment must had been started at least 3 months prior to Screening and the dose must had been stable for at least 3 months prior to Screening and should remain stable through Randomization;
  • •Sexually active female participants of childbearing potential must had agree to utilize a highly effective method of contraception per the Clinical Trial Facilitation Group Guidelines from Screening through 30 days after the last dose of study drug (1 month after the end of treatment), and agree to monthly pregnancy testing during the study up to and including end of study.
  • •Other inclusion criteria may apply

排除标准

  • •Had history of bariatric surgery or planned surgery during the study period;
  • •Had known history of heart disease;
  • •Had uncontrolled hypertension evidenced by sustained elevation in systolic blood pressure greater than140 mmHg or diastolic blood pressure greater than 90 mmHg despite treatment with antihypertensive therapy, prior to Randomization;
  • •Had a known history of Type 1 diabetes;
  • •Had a known history of acquired immunodeficiency syndrome or positive screening for human immunodeficiency virus antibodies at Screening Visit;
  • •Had a documented weight loss of more than 5% during the 6-month period prior to Randomization;
  • •Had a history of renal disease defined as an estimated glomerular filtration rate (eGFR) less than 90 mL/min/1.73 m^2 using the Schwartz Bedside GFR Calculator for Children or present at Screening Visit;
  • •History of, significant alcohol consumption or inability to reliably quantify alcohol intake, and/or use of illicit drugs.
  • •Had clinical and/or historical evidence of cirrhosis, included by not limited to:
  • •Abnormal hemoglobin (with the exception of females with a documented history of a low hemoglobin during menstruation);
  • •White blood cell count less than 3,500 cells/mm^3 of blood;
  • •Platelet count less than150,000 cells/mm^3 of blood;
  • •Direct bilirubin greater than 0.3 mg/dL;
  • •Total bilirubin greater than 1.3 mg/dL unless the patient has a diagnosis of Gilbert disease in which case direct bilirubin, reticulocyte count and haemoglobin must be normal;
  • •Serum albumin less than 3.5 g/dL;
  • •International normalized ratio (INR) greater than 1.4;
  • •Has evidence of chronic liver disease other than NASH, defined by any one of the following:
  • •Biopsy consistent with histological evidence of autoimmune hepatitis;
  • •Serum hepatitis A antibody positive;
  • •Serum hepatitis B surface antigen positive;
  • •Serum hepatitis C antibody positive;
  • •Serum hepatitis E antibody positive;
  • •History of or current positive Anti-Mitochondrial Antibody Test;
  • •Known or current Iron/total iron binding capacity ratio (transferrin saturation) greater than 45% with histological evidence of iron overload;
  • •Known or current Alpha-1-antitrypsin phenotype/genotype ZZ or SZ;
  • •Diagnosis of Wilson's disease;
  • •Had AST and/or ALT greater than 8 fold the upper limit of normal;
  • •Was pregnant, lactating or is planning to become pregnant during the study;
  • •Other exclusion criteria may apply

研究组 & 干预措施

Elafibranor 80 mg

Experimental

Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.

干预措施: Elafibranor 80mg (Drug)

Elafibranor 120 mg

Experimental

Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.

干预措施: Elafibranor 120mg (Drug)

结局指标

主要结局

Pharmacokinetics: Terminal Elimination Half-life ( t½) of Elafibranor and Active Metabolite (GFT1007)

时间窗: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

Plasma t1/2 was defined as the time taken by drug to reduce to half of its initial plasma concentration.

Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Elafibranor and Its Active Metabolite (GFT1007)

时间窗: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

Cmax was defined as maximum observed plasma concentration.

Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of Elafibranor and Active Metabolite (GFT1007)

时间窗: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

Tmax was defined as time to reach maximum observed plasma concentration.

Pharmacokinetics: Area Under The Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Elafibranor and Active Metabolite (GFT1007)

时间窗: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

AUC0-24 defined as the area under the plasma concentration versus time curve of the study drug from time 0 to 24 hours.

Pharmacokinetics: Plasma Trough Concentrations (Ctrough) of Elafibranor and Active Metabolite (GFT1007)

时间窗: Pre-dose on Day 1 and 29

Ctrough was defined as the plasma concentration of study drug observed just before treatment administration during repeated dosing.

次要结局

  • Pharmacodynamics - Other Liver Markers: Change From Baseline in Adiponectin at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Total Cholesterol (TC) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Triglycerides at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Change From Baseline in Body Weight at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Other Liver Markers: Change From Baseline in Cytokeratin 18 (CK-18)/M65 and CK-18/M30 at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics (PD) - Liver Markers: Change From Baseline in Serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), and Alkaline Phosphatase (ALP) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Other Liver Markers: Change From Baseline in Ferritin at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics - Other Liver Markers: Change From Baseline in Hyaluronic Acid, Procollagen 3 N-Terminal Propeptide (PIIINP) and Tissue Inhibitor of Metalloproteinase 1 (TIMP1) at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics - Other Liver Markers: Change From Baseline in Alpha-2 Macroglobulin at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Non High-density Lipoprotein Cholesterol (Non-HDL-C) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein B at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Inflammatory Marker: Change From Baseline in Plasminogen Activator Inhibitor-1 at Days 29, 57, 85, and 113(Baseline (Day 1), Day 29, 57, 85, and 113)
  • Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Insulin at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum High-density Lipoprotein Cholesterol (HDL-C) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Low-density Lipoprotein (LDL-C) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Calculated Very Low-density Lipoprotein Cholesterol (VLDL-C) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Change From Baseline in Waist Circumference at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Inflammatory Marker: Change From Baseline in Interleukin-6 at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Number of Participants With Abnormal Hematology and Coagulation Parameters(At Day 85 (i.e., end of treatment))
  • Number of Participants With Abnormal Vital Signs(At Day 85 (i.e., end of treatment))
  • Pharmacodynamics - Other Liver Markers: Change From Baseline in Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Plasma Glucose (FPG) at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Inflammatory Marker: Change From Baseline in Fibrinogen at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics - Change From Baseline in Pediatric Quality of Life (PedsQL™) (Version 4.0) Generic Core Scales at Day 85(Baseline (Day 1), Day 85)
  • Number of Participants With Abnormal Clinical Chemistry Parameters(At Day 85 (i.e., end of treatment))
  • Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein A-1 at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Inflammatory Marker: Change From Baseline in Tumor Necrosis Factor Alpha at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Pharmacodynamics - Change From Baseline in Body Mass Index (BMI) Z-Score at Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Pharmacodynamics - Inflammatory Marker: Change From Baseline in Haptoglobin at Days 29, 57, 85, and 113(Baseline (Day 1), Days 29, 57, 85, and 113)
  • Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Measurement(Baseline (Day 1), Day 85)
  • Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs(From Screening visit (signature of informed consent) up to last dose of study drug + 30 days (i.e., up to Day 113))
  • Number of Participants With Clinically Significant Abnormalities in Physical Examination at Baseline, Days 15, 29, 57, 85, and 113(Baseline (Day 1), Days 15, 29, 57, 85, and 113)
  • Number of Participants With Abnormal Urinalysis Parameters(At Day 85 (i.e., end of treatment))

研究者

发起方
Genfit
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
3 期
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)Myasthenia Gravis, Juvenile FormMyasthenia Gravis, GeneralizedMyasthenia Gravis
NCT03759366Alexion Pharmaceuticals, Inc.12
招募中
2 期
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia Gravis
NCT06055959UCB Biopharma SRL8
终止
3 期
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)Nonalcoholic Steatohepatitis (NASH) With Fibrosis
NCT02704403Genfit2,157
已完成
1 期
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired PatientsHepatic ImpairmentPharmacokineticsLiver Disease
NCT03765671Genfit30
已完成
3 期
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600gPsoriasis
NCT00096603Genentech, Inc.450